Overview

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Status:
RECRUITING

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

Phase:

PHASE3

Details

Lead Sponsor:

NovoCure GmbH

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

pembrolizumab
Temozolomide